Botulism is a neuroparalytic illness caused by botulinum neurotoxin (BoNT), a potent neurotoxin produced primarily by Clostridium botulinum and, rarely, by neurotoxigenic C. butyricum and C. baratii. BoNT blocks acetylcholine release at presynaptic cholinergic nerve terminals, producing flaccid paralysis involving somatic and autonomic neuromuscular junctions.^[1][2]

BoNT enters presynaptic cholinergic nerve terminals and prevents acetylcholine release by proteolytic disruption of SNARE proteins. The resulting neuromuscular blockade produces cranial-nerve dysfunction, descending skeletal-muscle paralysis, autonomic dysfunction, and potentially respiratory failure. Detailed toxin structure, SNARE targets, and neuronal recovery mechanisms are addressed in the Pathophysiology microchapter.^[3]

Four naturally occurring forms are recognized according to the route of toxin acquisition:

• Infant botulism — intestinal colonization with in situ toxin production in infants younger than 12 months, occurring predominantly before 6 months of age, with median onset at approximately 4 months.
• Foodborne botulism — ingestion of preformed BoNT, classically from improperly preserved, fermented, or home-canned foods.
• Wound botulism — wound colonization with in situ toxin production; strongly associated with injection drug use.
• Adult intestinal colonization botulism — rare intestinal colonization with in situ toxin production in adults.

Non-natural forms include iatrogenic botulism following excessive therapeutic or cosmetic BoNT exposure and inhalational botulism.^[4][5]

The characteristic syndrome is acute, afebrile, symmetric, descending flaccid paralysis beginning with cranial-nerve dysfunction in an alert patient with preserved sensorium. Early manifestations may include diplopia, blurred vision, ptosis, dysarthria, dysphonia, and dysphagia. Weakness may then descend to involve the trunk and limbs and progress to respiratory failure. Autonomic manifestations can include dry mouth, ileus or constipation, pupillary abnormalities, and blood-pressure or heart-rate lability.^[6][7]

Infant botulism commonly presents with constipation, poor feeding or weak suck, weak cry, ptosis, diminished gag reflex, loss of head control, and progressive hypotonia.^[8]

Botulism is rare. Reported annual United States case counts vary by surveillance period and source. Infant botulism constitutes the majority of reported cases, with foodborne and wound botulism accounting for smaller proportions.^[9][10]

Surveillance studies have demonstrated broader geographic recognition and reporting of infant botulism, while the extent to which this reflects changes in true incidence remains uncertain.^[11]

For foodborne botulism, symptom onset typically occurs approximately 2 hours to 8 days after exposure, with onset often occurring around 48 hours.^[12]

Diagnosis is fundamentally clinical. The combination of acute cranial-nerve dysfunction followed by symmetric descending weakness in an alert, generally afebrile patient should prompt consideration of botulism. Routine laboratory studies, cerebrospinal fluid examination, and neuroimaging are generally used to evaluate alternative diagnoses rather than to establish botulism.

Confirmatory testing may include detection of BoNT, toxin neutralization assays, culture, mass spectrometry, or nucleic acid amplification through public-health or reference laboratories. Results may take days; treatment should not be delayed while awaiting laboratory confirmation.^[13]

See Laboratory findings, Other diagnostic studies, and Differentiating for detailed diagnostic evaluation.

Management has two principal components: early passive immunization with botulinum antitoxin and meticulous supportive care, particularly respiratory and nutritional support.

• Infant botulism caused by toxin types A or B: human-derived botulism immune globulin intravenous (BIG-IV; BabyBIG), obtained through the California Infant Botulism Treatment and Prevention Program.
• All other forms and ages: equine-derived heptavalent botulinum antitoxin (BAT/HBAT), directed against serotypes A–G, obtained through the CDC. HBAT is also used for type F infant botulism and for foodborne or wound botulism occurring in an infant when indicated.^[14][15]
• Antitoxin neutralizes circulating toxin and prevents further neuronal uptake but does not reverse established paralysis. Benefit is greatest when treatment is administered within 48 hours of symptom onset, ideally within 24 hours, and declines with delay. Antitoxin should still be administered when clinically indicated even if more than 48 hours have elapsed.^[16][17][18]
• Supportive care includes close monitoring for respiratory failure, airway protection, mechanical ventilation when required, and nutritional support.
• Routine antibiotics are not indicated for foodborne or infant botulism. Antibiotic therapy may be used for wound botulism after antitoxin administration and for secondary infections.
• Aminoglycosides and clindamycin should be avoided/contraindicated when botulism is suspected because they can potentiate botulinum neuromuscular blockade and precipitate respiratory arrest.^{[19][20][21][22]}

Botulism is a notifiable condition requiring urgent public-health coordination. Suspected cases should prompt immediate consultation with the state or local health department for diagnostic testing and antitoxin access.^[23]

Detailed dosing, contraindications, adverse effects, monitoring, and adjunctive therapy are addressed in the Medical therapy microchapter.

Historical case-fatality rates were approximately 60% in the 1950s, compared with approximately 3%–5% with modern diagnosis, intensive care, and antitoxin therapy.^[24][25] Recovery of neuromuscular function generally occurs but may require weeks to months.

Detailed natural history, complications, predictors of outcome, and mortality are addressed in the Natural history, complications, and prognosis microchapter.

• Consider botulism when acute, symmetric, descending weakness begins with cranial-nerve dysfunction in an alert, afebrile patient.
• Preserved sensorium and descending weakness are important clinical clues.
• Do not wait for confirmatory laboratory testing before administering antitoxin when clinical suspicion is sufficient.^[26]
• Monitor closely for respiratory failure because neuromuscular weakness may progress despite preserved mental status.
• Antitoxin prevents additional toxin-mediated neuronal injury but does not reverse established paralysis.
• Select the antitoxin according to the clinical form and toxin type rather than age alone.
• Avoid aminoglycosides and clindamycin because of their potential to worsen neuromuscular blockade.

• Waiting for confirmatory laboratory testing before initiating antitoxin.
• Misdiagnosing botulism as Myasthenia gravis or Guillain-Barré syndrome.
• Failing to anticipate respiratory failure.
• Selecting BabyBIG for an infant with a form of botulism for which HBAT is indicated.
• Administering aminoglycosides or clindamycin to a patient with suspected botulism.
• Using routine antibiotics in foodborne or infant botulism.
• Assuming infant botulism is attributable only to a specific food exposure rather than considering environmental exposure.

Clostridium botulinum botulism was named In 1870 by Muller (German physician). In 1895 Clostridium botulinum was first isolated by Emile Van Ermengem and It was in 1949 when Burgen’s group discovered that botulinum toxin blocks neuromuscular transmission.

The first well-documented outbreaks of foodborne botulism were recorded in late 18th- and early 19th-century southwestern Germany (Kingdom of Württemberg), where consumption of spoiled meat and blood sausages caused numerous deaths.^[1]

The district medical officer and poet Justinus Kerner (1786–1862) published the first accurate and complete descriptions of the clinical syndrome between 1817 and 1822, correctly attributing it to a biological poison formed under anaerobic conditions that was lethal in minute quantities. He termed it “sausage poison,” and the illness became known as “Kerner’s disease.” ^[2][3]

Notably, Kerner recognized that the toxin disrupted somatic and autonomic cholinergic transmission while sparing sensory function and cognition, and he proposed—more than a century before it was realized—that it might be used therapeutically to reduce hypersecretion and abnormal movements. He is regarded as the intellectual founder of botulinum toxin therapy.^[3]

In 1895, Emile Pierre van Ermengem, professor of bacteriology at the University of Ghent, isolated the causative anaerobic bacillus following an outbreak of botulism after a funeral dinner featuring smoked ham in Ellezelles, Belgium. He named it after the Latin botulus (sausage), reflecting the disease’s historical association with sausage rather than the organism’s morphology.^[4][2]

Subsequent work established that botulism could arise from foods other than cured meats; a 1913 Stanford outbreak from a string-bean salad implicated home-canned vegetables, marking an important expansion in recognition of foodborne sources.^[3]

Edward Schantz began culturing Clostridium botulinum and developing bulk purification of the toxin in 1944, work that led to the 1946 crystallization of type A botulinum toxin.^[4]

In 1949, Arnold Burgen demonstrated that botulinum toxin acts by blocking acetylcholine release at the neuromuscular junction—the mechanistic basis for both the disease and its later therapeutic use.^[5][4]

Modern therapeutic use originated with ophthalmologist Alan B. Scott, who—building on Daniel Drachman’s observation that botulinum neurotoxin weakened chick hind-limb muscles—contacted Edward J. Schantz at Fort Detrick in 1968 seeking an injectable agent to weaken extraocular muscles as an alternative to strabismus surgery. Schantz, and later Eric A. Johnson, supplied purified botulinum neurotoxin type A.^[6]

Crystalline toxin was first injected into rhesus monkeys for strabismus in 1972, Scott published his primate results in 1973, and he first injected a human patient with strabismus in 1977.^[6][7]

Scott’s product, initially marketed as Oculinum, received its first FDA approvals in December 1989 for strabismus and blepharospasm associated with dystonia in patients 12 years and older. Allergan acquired Oculinum in 1991 and renamed it Botox.^[6][8]

Following the 1989 approval, indications broadened across neurology, ophthalmology, urology, dermatology, and other fields. Major historical milestones include:

• 2000 — onabotulinumtoxinA (Botox) and rimabotulinumtoxinB (Myobloc/NeuroBloc) were approved for cervical dystonia.
• 2002 — onabotulinumtoxinA (Botox Cosmetic) was approved for glabellar lines; the cosmetic effect had been reported by Jean and Alastair Carruthers in 1991.
• 2004 — onabotulinumtoxinA was approved for severe primary axillary hyperhidrosis.
• 2009 — abobotulinumtoxinA (Dysport) was approved; the FDA introduced distinct nonproprietary “-botulinumtoxin” names to distinguish non-interchangeable products.
• 2010 — onabotulinumtoxinA was approved for chronic migraine and upper-limb spasticity; incobotulinumtoxinA (Xeomin) was approved for cervical dystonia and blepharospasm.
• 2011 — onabotulinumtoxinA received FDA approval for urinary incontinence due to neurogenic detrusor overactivity (idiopathic overactive bladder with urge incontinence followed in 2013).^[9]

Four botulinum neurotoxin products are described in the source evidence as approved in the United States: onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and rimabotulinumtoxinB (Myobloc). Their units of potency are not interchangeable.^[10][11]

• Kerner (1817–1822) — first detailed clinical description of botulism and early proposal for therapeutic use of the toxin.
• van Ermengem (1895) — isolation of the causative organism.
• Schantz (1944–1946) — purification work leading to crystallization of type A toxin.
• Burgen (1949) — demonstration of blockade of acetylcholine release at the neuromuscular junction.
• Scott and Schantz (1968–1977) — development of therapeutic botulinum toxin for strabismus, progressing from the initial collaboration to animal studies and the first human treatment.
• FDA approval (1989) — beginning of the modern approved therapeutic era with Oculinum.

The historical development of independently manufactured botulinum neurotoxin products also explains why their potency units are not interchangeable; units should not be converted between products using a simple equivalence factor.^[8][10]

Template:WikiDoc Sources

Botulism is classified along two complementary axes: (1) the route by which botulinum neurotoxin (BoNT) reaches the circulation (transmission category), which determines epidemiology, diagnostic sampling, and public-health response; and (2) the BoNT serotype and the neurotoxigenic Clostridium species that produced it, which determines antitoxin coverage and laboratory confirmation. All forms share an identical final clinical syndrome—symmetric cranial-nerve palsies followed by descending, symmetric flaccid paralysis with preserved sensorium—because the toxin’s mechanism at the neuromuscular junction is the same regardless of route.^[1][2]

Four naturally occurring forms are recognized, distinguished by whether preformed toxin is ingested versus produced in situ by colonizing organisms:^[1][3]

• Infant botulism — intestinal colonization by ingested spores, with germination and in situ toxin production in infants younger than 12 months (predominantly <6 months). It is the most common form in the United States. Honey is an avoidable but uncommon identified source; most cases involve environmental spore exposure (soil, dust) rather than a specific food.^[4][5]
• Foodborne botulism — ingestion of preformed toxin from food in which spores germinated and produced toxin under anaerobic, low-acid, low-salt/low-sugar conditions. Home-canned/preserved vegetables and fermented fish are classic vehicles; commercially processed foods and prison-made wine (“pruno”) are less common sources.^[6][7]
• Wound botulism — wound contamination, germination, and in situ toxin production. Most modern cases arise from injection drug use (“skin popping,” black-tar heroin); gross trauma or crush injury is a less common predisposing event. It is not the rarest form. Fever may be present when the wound is secondarily infected, unlike other forms.^[8][9]
• Adult intestinal colonization (toxemia) botulism — the adult/older-child analogue of infant botulism, in which ingested spores colonize the intestine and produce toxin in situ. It is exceedingly rare and typically requires a predisposing alteration of gut anatomy or flora—prior bowel or gastric surgery, short-bowel syndrome, inflammatory bowel disease/Crohn disease, anatomical bowel abnormalities, or recent antimicrobial therapy.^[10][11]

Incubation periods differ by form and aid classification: foodborne botulism typically 12–48 hours (range 6 hours–10 days), infant botulism an estimated 3–30 days, and wound botulism 4–14 days from injury.^[12]

The mechanistic dividing line is diagnostically important: foodborne botulism involves ingested preformed toxin (no ongoing intestinal production), whereas infant and adult intestinal colonization botulism involve ongoing in situ production, so neurotoxigenic clostridia may be shed in stool for weeks.^[13]

• Iatrogenic botulism — systemic weakness following injection of excess therapeutic or cosmetic BoNT (e.g., for dystonia, spasticity, migraine, or cosmesis).^[14][15]
• Inhalational botulism — results from aerosolized toxin; it does not occur naturally and is chiefly relevant as a bioterrorism scenario. BoNT is a CDC Category A bioterrorism agent.^[16]

A useful mnemonic distinction: infant, foodborne, and adult intestinal forms enter via the gastrointestinal route; wound via tissue; and iatrogenic/inhalational via injection or aerosol.^[17]

BoNTs are divided into seven classical immunologically distinct serotypes (BoNT/A–G), further resolved into more than 40 subtypes by amino-acid sequence variation within the bont gene. Newer literature describes additional or novel toxin types beyond the classical seven—including the chimeric BoNT/HA (also called type H or F/A), BoNT/X, and a toxin encoded by Enterococcus (eBoNT/J)—and some recent sources therefore cite up to nine serotypes (A–H and X); the classical A–G framework remains standard for clinical purposes.^[18][19][20]

• Serotypes causing human disease: A, B, E, and F. Serotypes A and B are the most prevalent in the United States.^[21]
• Producing organisms: most disease is caused by Clostridium botulinum, but neurotoxigenic strains of C. butyricum (typically type E) and C. baratii (typically type F) produce clinically identical illness. Type F C. baratii is a recognized cause of both infant botulism and adult intestinal toxemia botulism.^[22][23]

Serotype matters for treatment-product selection: human-derived BIG-IV (BabyBIG) covers toxin types A and B, whereas equine heptavalent antitoxin (HBAT) covers serotypes A–G (see Medical therapy).^[24]

• Establish the transmission category early, because it dictates specimen collection (stool/enema for colonization forms; serum for all; wound culture for wound botulism; implicated food for foodborne) and public-health actions.^[25]
• Do not withhold antitoxin while awaiting serotype identification; product choice depends on the clinical form and age, and treatment is time-critical.^[26]
• Consider adult intestinal colonization botulism in a patient with the classic syndrome, no food or wound source, and a predisposing gut condition.^[27]

The pathophysiology of botulism is defined by botulinum neurotoxin (BoNT), a zinc-dependent metalloprotease that enters peripheral cholinergic nerve terminals and cleaves SNARE proteins, blocking calcium-triggered acetylcholine release. The resulting failure of neurotransmission at somatic and autonomic cholinergic synapses produces the characteristic symmetric, descending flaccid paralysis with autonomic dysfunction and preserved sensorium and cognition. This single mechanism—identical regardless of how the toxin is acquired—accounts for the clinical syndrome, the diagnostic strategy, the time-critical rationale for antitoxin, and the characteristically slow recovery.^[1][2]

BoNT is synthesized as a single ~150-kDa inactive polypeptide that is activated by proteolytic (“nicking”) cleavage into a di-chain molecule: a ~100-kDa heavy chain (HC) and a ~50-kDa light chain (LC) joined by a single interchain disulfide bond.^[3][4]

Three functional modules map directly to the three steps of intoxication:

• LC — a zinc-dependent endopeptidase; the catalytic warhead that cleaves SNARE proteins.
• HC C-terminal receptor-binding domain (H_C) — mediates highly selective binding to presynaptic nerve terminals.
• HC N-terminal translocation domain (H_N) — forms the endosomal pore that delivers the LC to the cytosol.^[5][6]

In naturally produced (progenitor) toxin complexes, the neurotoxin is bound to nontoxic accessory proteins (NTNH and hemagglutinins). These shield the toxin from gastric acid and proteases and facilitate absorption across the intestinal epithelium—explaining how an ingested protein toxin survives the gut to reach the circulation.^[7]

BoNT is the most poisonous substance known, with an estimated human lethal dose of ~1 ng/kg intravenously (LD₅₀ estimates 0.1–1 ng/kg), reflecting the catalytic amplification of a single enzyme molecule acting on many substrate copies.^[8][9]

Intoxication proceeds through a conserved four-step sequence at the presynaptic terminal:^[10]

1. Binding — H_C engages a presynaptic receptor via a dual-receptor mechanism: a complex polysialoganglioside (e.g., GT1b) concentrates the toxin at the membrane, and a protein receptor confers specificity and uptake. BoNT/A, D, E, and F use synaptic vesicle glycoprotein 2 (SV2); BoNT/B and G use synaptotagmin. The protein receptors are transiently exposed on the cell surface during synaptic-vesicle exocytosis, so binding is activity-dependent. For BoNT/A, efficient synaptic-vesicle entry requires a tripartite PSG–synaptotagmin-1–SV2 nanocluster rather than SV2 alone.^[11][12][13]
2. Internalization — the receptor-bound toxin is endocytosed into recycling synaptic vesicles.^[14]
3. Translocation — vesicular acidification triggers H_N to form a transmembrane pore; the LC translocates into the cytosol, and the disulfide bond is reduced to release the free, active LC.^[15][16]
4. SNARE cleavage — the cytosolic LC cleaves a specific SNARE protein, preventing assembly of the four-helix SNARE bundle needed for Ca²⁺-triggered vesicle fusion, thereby abolishing acetylcholine release.^[17]

Because binding, internalization, and cleavage occur intracellularly, antitoxin can neutralize only circulating toxin that has not yet entered nerve terminals; it cannot reverse SNARE cleavage already accomplished inside the neuron. This is the mechanistic basis for administering antitoxin as early as possible.^[18]

The seven classical serotypes cleave one of three SNARE proteins, each at a serotype-specific site:^[19][20]

• SNAP-25 — cleaved by BoNT/A, /C, and /E.
• VAMP/synaptobrevin-2 — cleaved by BoNT/B, /D, /F, and /G.
• Syntaxin-1 — cleaved by BoNT/C (the only classical serotype that cleaves two substrates, SNAP-25 and syntaxin).

Serotypes A, B, E, and F cause essentially all human disease. The precise cleavage site differs even between serotypes sharing a substrate, which underlies neoepitope-based laboratory detection.^[21][22]

The duration of neuromuscular blockade is serotype-dependent, reflecting the persistence of the LC and the stability of its cleavage product. BoNT/A cleaves only nine C-terminal residues from SNAP-25, producing a truncated fragment that persists and exerts a dominant-negative effect on the residual intact machinery, contributing to blockade lasting months. BoNT/E removes a larger C-terminal segment, yielding a less stable product and a shorter effect (days to weeks); BoNT/F is similarly short-acting. These differences explain why type A (and B) intoxication produces prolonged paralysis.^[23][24]

BoNT blocks acetylcholine release at both somatic neuromuscular junctions and autonomic (sympathetic and parasympathetic ganglionic and postganglionic cholinergic) synapses, but does not affect adrenergic transmission, sensory nerves, or the central nervous system. The toxin does not cross the blood–brain barrier. This cholinergic selectivity explains the constellation of motor weakness plus autonomic features (dry mouth, ileus, fixed/dilated pupils, labile heart rate and blood pressure) with intact sensation and normal mentation—a diagnostically pivotal pattern.^[25][26]

Denervated muscle fibers behave as functionally denervated (chemodenervation), atrophy, and may show fibrillations and positive sharp waves—findings that inform electrodiagnostic interpretation.^[27]

Clinical recovery requires restoration of functional neurotransmission, which occurs through two processes rather than clearance of the toxin:

• Collateral axonal sprouting — in response to blockade, the presynaptic terminal produces sprouts that form new, transiently functional connections with the muscle; for BoNT/A, sprout remodeling begins around day 4, sprouts become functional from approximately day 7, and they peak near day 42 before regressing.^[28][29]
• Recovery of the original terminal — the parent neuromuscular junction regains function and is the dominant source of restored transmission (>80% of quantal release in experimental models), after which the transient sprouts retract; full recovery may take weeks to months.^[30][31]

A key conceptual point is that molecular persistence and functional recovery occur on different timescales: intracellular LC activity and cleaved-SNAP-25 burden can persist far longer than the restoration of muscle force, with reinnervation/remodeling bridging the two.^[32]

• Administer antitoxin as early as possible: it neutralizes only extracellular toxin and cannot reverse blockade in terminals already intoxicated.^[33]
• Anticipate prolonged, ventilation-dependent weakness: recovery depends on nerve-terminal sprouting and reinnervation over weeks to months, not toxin clearance.^[34]
• Use the cholinergic (motor + autonomic) pattern with preserved sensation and cognition as a mechanistic diagnostic anchor.^[35]

Botulism is caused by botulinum neurotoxin (BoNT), produced by Clostridium botulinum and, less commonly, by neurotoxigenic strains of Clostridium butyricum (typically type E) and Clostridium baratii (typically type F). Disease results from absorption of toxin into the circulation from a gastrointestinal (mucosal) or wound surface. The causative exposure differs by clinical form: ingestion of preformed toxin (foodborne botulism) versus ingestion or wound inoculation of spores that germinate and produce toxin in situ (infant, adult intestinal colonization, and wound botulism). BoNT/A, B, E, and rarely F cause essentially all human disease, with serotypes A and B most prevalent in the United States.^[1][2][3]

• Clostridium botulinum — a Gram-positive, spore-forming, obligate anaerobic bacillus that is ubiquitous in soil and aquatic sediment worldwide. It is a heterogeneous species comprising four physiologic groups (I–IV); human disease is caused almost exclusively by Group I (proteolytic; types A, B, F) and Group II (non-proteolytic; types B, E, F). Group III causes animal disease, and Group IV (reclassified C. argentinense, type G) has not been linked to naturally occurring human or animal illness.^[4][5]
• Related neurotoxigenic clostridia — C. butyricum (Group VI) can produce type E toxin and C. baratii (Group V) can produce type F toxin, each causing clinically identical illness, including infant botulism. Type F C. baratii disease can progress rapidly.^[6][7]

The organism itself is non-invasive; all pathology derives from the neurotoxin. Detailed serotype–SNARE biology is covered in Pathophysiology; the group/serotype taxonomy is covered in Classification.

Seven classical, immunologically distinct serotypes (BoNT/A–G) are recognized, with more than 40 subtypes; additional molecules (the A/F hybrid “H”/HA/FA and BoNT/X) have been described.^[8][9]

• A, B, E, and rarely F cause human botulism; A and B predominate in the United States.^[10]
• Type E is classically associated with fish and other marine/aquatic and high-latitude sources and can grow and produce toxin at refrigeration temperatures (Group II is psychrotrophic).^[11][12]
• Types C and D cause animal disease; type G has not been assigned to a natural human outbreak.^[13]

Serotype tends to track the causative source: types A and B predominate in home-canned/preserved vegetables and other terrestrial foods, whereas type E is characteristically linked to fish and aquatic/marine sources.^[14][15]

BoNT is synthesized during late-exponential/stationary-phase growth and released on bacterial cell lysis; its synthesis is co-regulated with sporulation (via the transcription factor Spo0A), and toxin is liberated together with the mature spore on mother-cell lysis. The key clinical point is that spores—the environmentally resistant, dormant form—must first germinate and multiply before neurotoxin appears. Growth and toxin production require a permissive combination of conditions that is rarely met simultaneously, which explains the rarity of disease.^[16][17][18]

Permissive conditions include:^[19][20]

• Anaerobic environment (e.g., sealed cans/jars, deep wounds, the infant gut lumen).
• Low acidity — pH >4.6; toxin is not formed reliably below pH 4.6, the basis for acidification as a food-safety control. Active growth occurs over approximately pH 4.8–8.5; the pH 4.6 cutoff is the regulatory threshold separating “acid” from “low-acid” foods, and toxin formation below pH 4.6 occurs only under unusual strictly anaerobic, high-protein conditions.
• Low salt and low sugar content, and adequate water activity.
• Permissive temperature — growth occurs roughly between 3°C and 48°C; Group II strains (types B, E, F) can grow at refrigeration temperatures, a concern for minimally processed chilled foods. Non-proteolytic Group II strains have produced toxin at temperatures as low as 3°C in experimental and food-matrix studies, underscoring the risk in minimally processed, vacuum-packed, or sous-vide chilled foods where refrigeration is the primary control.^[21][22]

Heat behavior is central to prevention: the toxin is heat-labile (inactivated at ~80°C for 30 min or 100°C for ~5 min), whereas spores are highly heat-resistant (Group I spores survive prolonged boiling and require the “botulinum cook,” 121°C for ~3 min under pressure, as used in low-acid canning).^[23][24]

A mechanistic distinction underlies specimen selection: foodborne botulism involves ingested preformed toxin with no ongoing intestinal production, whereas infant, adult intestinal colonization, and wound botulism involve in situ toxin production, so neurotoxigenic clostridia may be shed in stool for weeks (documented for 41–61 days in adult intestinal colonization).^[25][26]

Results from eating food in which spores germinated and produced toxin under anaerobic, low-acid conditions. The most common causes in the United States are improperly home-canned/preserved foods and inadequately refrigerated cooked foods; less common sources include commercially processed foods, restaurant-associated foods, fermented fish, and prison-made wine (“pruno”).^[27][28]

Results from ingestion of spores that germinate and colonize the large intestine, producing toxin in situ in infants younger than 12 months. Honey is the only avoidable food source definitively linked to disease, but it accounts for a minority of cases (≈4% in recent US data); most US cases are attributed to ingestion of ubiquitous environmental/airborne dust and soil spores. Rarely implicated foods include powdered infant formula (nonsterile), dry cereals, and herbal teas. Corn syrup has not been proven to cause disease.^[29][30][31]

Results from contamination of devitalized tissue with spores that germinate under anaerobic conditions and produce toxin. Most modern cases arise from injection drug use (“skin popping,” black-tar heroin; rarely methamphetamine); gross trauma or crush injury is a less common predisposing event. Unlike other forms, fever may be present when the wound is secondarily infected.^[32][33]

The adult/older-child analogue of infant botulism, in which ingested spores colonize the gut and produce toxin in situ. It is exceedingly rare and typically requires a predisposing alteration of gut anatomy or flora—prior bowel or gastric surgery, inflammatory bowel disease, or recent antimicrobial exposure.^[34][35]

Iatrogenic botulism follows injection of excess therapeutic/cosmetic BoNT; inhalational botulism does not occur naturally and is chiefly a bioterrorism concern (BoNT is a CDC Category A agent).^[36]

• Determine the likely causative exposure early: it directs specimen collection (serum for all; stool/enema for colonization forms; wound culture; implicated food) and public-health action.^[37]
• Do not feed honey to infants younger than 12 months, but do not exclude infant botulism when honey exposure is absent—most cases are environmental.^[38]
• Ask about injection drug use in any adult with an unexplained descending paralysis, even without an obvious wound.^[39]
• Counsel that boiling inactivates toxin but not spores; safe home canning requires pressure processing of low-acid foods.^[40]

Template:WikiDoc Sources

Botulism produces an acute, afebrile, symmetric, descending flaccid paralysis that begins with cranial-nerve (oculobulbar) dysfunction in an alert patient with intact sensation. It must be differentiated from other disorders of the neuromuscular junction, peripheral nerve/root, motor neuron, muscle, and brainstem, as well as from neurotoxin exposures that impair cholinergic transmission. In a CDC series of 332 U.S. cases (>12 months of age), the illnesses most often on the treating physician’s differential were Guillain-Barré syndrome (GBS) and myasthenia gravis (MG); classic features were common, but “atypical” findings (e.g., paresthesias in 17%, elevated CSF protein in 13%, unilateral or ascending findings in a minority) were also reported, so no single feature excludes the diagnosis.^[1][2] Because treatment is time-critical and clinical, differentiation should proceed in parallel with, not before, antitoxin decision-making.

The following features, taken together, favor botulism over its mimics:^[3][4]

• Descending course beginning with the eyes/bulbar muscles (diplopia, ptosis, dysarthria, dysphagia), in contrast to the classically ascending pattern of GBS and tick paralysis.
• Symmetric weakness with preserved sensorium and no true sensory loss (paresthesias may rarely occur).
• Afebrile presentation (fever suggests a superimposed infection or an alternative diagnosis; it may occur in wound botulism).
• Autonomic/cholinergic signs: fixed or sluggish dilated pupils (mydriasis), dry mouth, ileus/constipation, urinary retention.
• Normal CSF (protein usually normal), normal neuroimaging, and a characteristic electrodiagnostic profile (below).

Detailed test performance and interpretation are covered in Laboratory findings and Other diagnostic studies.

In infant botulism (≈95% of confirmed cases occur before 6 months of age), the most common admitting diagnosis is sepsis; as hypotonia progresses, the differential broadens.^[14] Analyses of infants treated with BIG-IV but not confirmed to have botulism (“clinical mimics”) identify five recurring categories: spinal muscular atrophy type I, metabolic disorders, other infectious diseases, miscellaneous conditions, and probable (untested) infant botulism.^[15]

• Sepsis/meningoencephalitis — febrile, ill-appearing; positive cultures/CSF.^[16]
• Spinal muscular atrophy type I — longer history of weakness; spares extraocular muscles and sphincters (both characteristically involved in botulism); tongue fasciculations; SMN1 genetic testing.^[17]
• Transient neonatal / congenital myasthenic syndromes — onset in first days of life; maternal MG history (transient form); genetic testing.^[18]
• Metabolic/inborn errors, hypothyroidism — targeted metabolic and endocrine studies.^[19]
• GBS (including Miller Fisher) — rare in infancy, occurs in older children; elevated CSF protein and NCS/EMG distinguish it.^[20]

The edrophonium (Tensilon) test is generally not indicated in infants, because congenital MG is excluded by history and de novo autoimmune MG does not occur at this age.^[21]

Electrodiagnostic testing is the single most useful ancillary study for separating botulism from GBS, MG, and LEMS:^[22][23]

• Botulism: low resting CMAP amplitudes with normal motor conduction velocities and normal sensory studies; post-exercise facilitation and an incremental response to high-frequency (30–50 Hz) RNS — the most distinctive finding. Small, short-duration MUAPs on needle EMG. Facilitation in botulism is typically less pronounced than in LEMS but more persistent (minutes).
• MG: decrement on low-frequency (2–3 Hz) RNS; normal CMAP at rest; abnormal SFEMG jitter.^[24]
• LEMS: low resting CMAP with marked (>60–100%) post-exercise facilitation and decrement at low-frequency RNS.^[25]
• GBS: demyelinating features (prolonged distal latencies, conduction block, slowed velocities, prolonged/absent F-waves); electrodiagnostic abnormalities may be delayed in the first week.^[26]

Caveats: In botulism, incremental responses may be absent early or in severe cases, and both HFRNS and post-exercise facilitation lose sensitivity in the post-acute phase; a normal study does not exclude botulism.^[27][28]

• Use the descending vs. ascending distinction and pupillary/autonomic signs as first-line bedside discriminators; confirm with EDx and toxin testing.^[29]
• Do not delay antitoxin while excluding mimics; empiric treatment on clinical suspicion is standard.^[30]
• Search thoroughly for an attached tick (scalp, groin) in any acute ascending flaccid paralysis—removal is curative and averts unnecessary testing.^[31]
• Clustering of cases of symmetric descending paralysis strongly suggests botulism (or shellfish/toxin exposure) and mandates immediate public-health notification.^[32]

Template:WikiDoc Sources

Botulism is a rare, reportable disease that occurs worldwide. In the United States, an average of roughly 200 cases are reported annually, of which approximately three-fourths are infant botulism; foodborne, wound, and “other” (iatrogenic, adult intestinal colonization, and unknown-route) cases make up the remainder.^[1][2] Since 1973 the CDC, with the Council of State and Territorial Epidemiologists, has maintained the National Botulism Surveillance System, which classifies laboratory-confirmed cases as foodborne, wound, infant, or other. Because botulism antitoxin in the United States is available only through the CDC, the Alaska Division of Public Health, and (for infants) the California-based Infant Botulism Treatment and Prevention Program, nearly all recognized cases are captured, although mild or misdiagnosed cases are under-ascertained.^[3] Case counts differ by ascertainment system: the ~200 cases/year figure derives from CDC National Botulism Surveillance, whereas the ~130–159 infant cases/year figure derives from Infant Botulism Treatment and Prevention Program BIG-IV request data; both are subject to under-ascertainment.^[4]

Historical baseline surveillance (since 1973) recorded medians of approximately 24 foodborne, 3 wound, and 71 infant cases per year.^[5] Contemporary data show infant botulism has risen substantially while foodborne and wound botulism have remained lower or event-driven.

• Infant botulism (most common form). From 2007–2021, 1947 U.S. cases were recognized (an average of ~130 cases/year), with a statistically significant upward linear trend and a 5-year average of 159 cases/year for 2017–2021. National incidence was 3.3 cases per 100,000 live births.^[6]
• Foodborne botulism. Roughly 15%–25% of annual cases historically; the 2006–2010 annual average was ~17 cases. From 1990–2000, 263 cases occurred in 160 events, with 39% of cases in Alaska.^[7][8]
• Wound botulism. Historically only a few cases per year, but sharply increased since the mid-1990s because of injection drug use. More than 350 U.S. wound botulism cases were reported to the CDC during 2001–2016, of which 292 (>80%) occurred in California.^[9]
• Other (iatrogenic, adult intestinal colonization, unknown route). Adult intestinal colonization botulism is very rare, typically following intestinal surgery or antimicrobial exposure. Cosmetic/therapeutic iatrogenic botulism is an emerging category (below).^[10]

• Infant botulism occurs in infants younger than 12 months; in 40-year California surveillance (1345 cases, 1976–2016), 88% were ≤6 months of age, and breastfed infants presented later (median 4.4 months) than formula-fed infants (median 1.7 months).^[11]
• Foodborne and wound botulism occur across all ages; foodborne median age is ~48–53 years. In Alaska Native persons, foodborne incidence is highest in those aged ≥60 years.^[12][13]

Overall, men and women are affected approximately equally. Infant botulism shows no male predominance (51.2% male nationally, 2007–2021; 51% female in California). Foodborne cases have shown a female majority (~59%). Wound botulism among injection drug users has occurred disproportionately in women and Hispanic persons in California.^[14][15]

No intrinsic racial predilection is established for botulism overall. Distribution reflects exposure: in California infant botulism, 84.2% of cases were white and 29.4% Hispanic; endemic foodborne botulism in Alaska is concentrated among Alaska Native persons because of traditional food practices.^[16][17]

• Infant botulism clusters in the arid West/Southwest and in a temperate mid-Atlantic band. State incidence per 100,000 live births (2007–2021) far exceeds the national rate of 3.3 in Delaware (20.4), Pennsylvania (12.1), New Jersey (7.5), Maryland (6.7), Utah (7.5), California (7.7), and New Mexico (4.7).^[18]
• Foodborne botulism concentrates in the West and in Alaska; historically, more than 50% of U.S. foodborne outbreaks since 1950 have been reported from California, Washington, Colorado, Oregon, and Alaska. Alaska incidence among Alaska Native persons (~6.9/100,000/year) is more than 800 times the overall U.S. rate.^[19][20]
• Wound botulism is overwhelmingly concentrated in California among people who inject black tar heroin.^[21]

• Foodborne (U.S.): type A ~50–51%, types B and E ~25% each; type E predominates in Alaska (90% of Alaska cases) and the Great Lakes region and is associated with fish/aquatic foods. Type A predominates in western states, type B in eastern states.^[22][23]
• Infant (U.S., 2007–2021): type B 58.3%, type A 39.4%.^[24]

Mortality has fallen markedly with modern intensive care and timely antitoxin. Foodborne case-fatality decreased from ~25% (1950–1959) to ~6% (1990–1996); contemporary overall mortality is approximately 5%. Alaska foodborne case-fatality was 8.2% overall (1947–2007) but ≤4% since 1980, with misdiagnosis associated with higher mortality and delayed antitoxin.^[25][26][27]

Iatrogenic botulism from therapeutic and, increasingly, cosmetic botulinum toxin injection is a growing epidemiologic category, driven by counterfeit/unlicensed products, unlicensed practitioners, and off-label high-dose use (e.g., injections for weight loss/gastric procedures). Large single-center series have reported dozens to >160 cosmetic iatrogenic cases, with clusters in 2023–2024; severe cases have required prolonged mechanical ventilation.^[28][29][30]

^[31][32][33]

C. botulinum spores are present in soil on all continents except Antarctica, and foodborne botulism occurs worldwide. Infant botulism, however, is reported very unevenly: incidence is high in Argentina (~7.0/100,000 live births) and parts of the western United States, but low in Europe (0.1–0.4) and Canada (0.5), rare in China (~0.014), and essentially unreported in Russia and most of Africa. Case clustering in arid, desert, and Mediterranean-climate regions is a recurring global pattern.^[34]

• Infant botulism is the dominant U.S. form and is increasing; suspect it in any afebrile hypotonic infant <12 months regardless of honey exposure.^[35]
• Ask about injection drug use (black tar heroin, skin popping) in any adult with descending paralysis, especially in California.^[36]
• Consider cosmetic/therapeutic iatrogenic botulism in patients with recent botulinum toxin injection, particularly from unlicensed sources.^[37]
• Any cluster of cases mandates immediate health-department notification.^[38]

Template:WikiDoc Sources

Risk factors for botulism are best understood by transmission category, because the exposure that permits toxin production differs by form. For infant and adult intestinal colonization botulism, the risk is ingestion of C. botulinum spores that then colonize a susceptible gut. For foodborne botulism, the risk is ingestion of preformed toxin from improperly preserved food. For wound botulism, the risk is contamination of devitalized tissue, now overwhelmingly from injection drug use. Iatrogenic botulism is an emerging category driven by cosmetic/therapeutic botulinum toxin injection.^[1][2]

Infant botulism results from ingested spores that germinate in the immature large intestine, where the developing microbiota does not yet suppress colonization. Recognized risk factors include:^[3][4]

• Age younger than 12 months (susceptible gut flora), with ~88% of cases occurring at ≤6 months of age.^[5]
• Environmental spore exposure — the leading presumed source in the United States: airborne/household dust, nearby soil disturbance, construction, and rural or agricultural living.
• Honey ingestion — the only definitively established, avoidable food source, but responsible for a minority of U.S. cases (~4%); honey exposure is higher among European and Middle Eastern cases.
• Rarely implicated foods — powdered (nonsterile) infant formula, infant rice cereal, well water, and herbal teas (e.g., chamomile) have each been linked in isolated reports.

Corn syrup has never been proven to cause infant botulism, and lack of honey exposure does not exclude the diagnosis.^[6][7]

Foodborne botulism follows ingestion of preformed toxin from food in which spores germinated under anaerobic, low-acid (pH >4.6), low-salt, low-sugar conditions. Risk factors relate to food handling rather than the host:^[8][9]

• Improper home canning/preservation of low-acid foods (the most common U.S. cause) — home-canned vegetables (asparagus, green beans, beets, corn), and, in ethnic cuisines, home-preserved items such as prickly-pear cactus (nopales) and bamboo shoots.
• Inadequate refrigeration of cooked foods, including foil-wrapped baked potatoes and oil infusions (e.g., garlic-in-oil).
• Fermented aquatic foods — fermented fish/marine mammal products (Alaska Native cuisine; type E).
• Uncommon vehicles — commercially processed foods, restaurant-held foods, and prison-made illicit alcohol (“pruno”).

Wound botulism requires contamination of devitalized tissue with spores that germinate anaerobically. Risk factors:^[10][11]

• Injection drug use — the dominant modern risk factor, especially black tar heroin and subcutaneous/intramuscular injection (“skin popping”), with a dose-response relationship to the amount injected; rarely methamphetamine. Compared with injectors who never skin-popped, occasional skin-poppers had ~6-fold and heavy users ~25-fold higher adjusted odds of wound botulism.^[12]
• Chronic intranasal cocaine use with sinus/nasal lesions (rare).
• Gross traumatic or crush injury with devitalized/contaminated tissue (historically predominant; now less common), including open fractures.

This rare form is the adult/older-child analogue of infant botulism, in which ingested spores colonize an abnormal gut. Predisposing risk factors:^[13][14]

• Prior bowel or gastric surgery, short-bowel syndrome, or anatomical bowel abnormalities.
• Inflammatory bowel disease / Crohn disease and small-intestinal bacterial overgrowth.
• Recent antimicrobial therapy (disrupts protective flora).

Iatrogenic botulism follows systemic spread of injected botulinum toxin. Risk factors identified in recent case series:^[15][16][17]

• Unlicensed, counterfeit, or unknown-brand products.
• Injection in non-authorized institutions / by untrained injectors.
• Excessive or off-label high-dose administration (higher dose is associated with shorter latency to symptoms).

• Advise against feeding honey to infants <12 months, but do not exclude infant botulism when honey exposure is absent—most U.S. cases are environmental.^[18]
• Screen for injection drug use (skin popping, black tar heroin) in any adult with descending paralysis, even without an obvious wound; consider botulism when weakness fails to respond to naloxone.^[19]
• Ask about recent cosmetic/therapeutic botulinum toxin injection, especially unlicensed products, in new-onset bulbar/descending weakness.^[20]
• Suspect adult intestinal colonization in the classic syndrome with no food/wound source and a predisposing gut condition.^[21]

Template:WikiDoc Sources

There is no screening test for botulism and no professional-society or U.S. Preventive Services Task Force (USPSTF) recommendation for screening asymptomatic individuals; USPSTF has never issued a botulism screening statement. Botulism is a rare, acute, non-communicable intoxication that does not have an asymptomatic or preclinical detectable phase amenable to screening; it therefore fails standard screening (Wilson-Jungner) criteria. Instead of screening, the relevant public-health activities are mandatory case reporting, surveillance, rapid clinical recognition, and outbreak case-finding, with close observation (not laboratory screening) of asymptomatic exposed persons.^[1][2]

Botulism does not meet the conditions that make screening useful:^[3][4]

• No detectable asymptomatic/latent phase in which early detection would change outcome; disease is defined by acute neurologic signs.
• Very low prevalence (a few hundred U.S. cases/year across all forms), which would render any screening test’s positive predictive value negligible.
• Confirmatory tests are slow and reference-laboratory–based (mouse bioassay, mass spectrometry, NAAT for BoNT genes) and are designed to confirm clinically suspected disease, not to screen well people.
• Diagnosis is clinical and treatment is empiric: antitoxin is given on clinical suspicion without waiting for testing, so a screening paradigm offers no benefit.

• Mandatory reporting. Botulism of any type is a nationally notifiable condition; in most U.S. jurisdictions a case suspected on clinical grounds alone must, by law, be reported immediately (by telephone) to local/state health authorities. State health departments maintain 24-hour service, and the CDC Clinical Emergency Botulism Service is available at 770-488-7100.^[5][6]
• National surveillance. Since 1973 the CDC has maintained national botulism surveillance; because antitoxin is released only through public-health channels, nearly all recognized cases are captured, supporting outbreak detection and trend monitoring.^[7]
• Heightened clinical detection. CDC outbreak guidance provides a diagnostic tool and urges clinicians to consider botulism in patients labeled as myasthenia gravis, Guillain-Barré syndrome, or isolated symmetric facial/bulbar weakness, and to watch for early respiratory failure—an approach that functions as active case detection during outbreaks.^[8]
• Newborn screening. Botulism is not included in newborn screening programs; infant botulism is identified by clinical recognition and confirmatory testing of symptomatic infants, not by screening.^[9]
• Outbreak case-finding. Once one case is identified, public-health investigation actively seeks additional exposed persons (e.g., shared food source), collects implicated foods, and obtains serum/stool from co-exposed symptomatic persons—case-finding, not asymptomatic screening.^[10]

Asymptomatic persons known to have ingested a food containing (or suspected of containing) botulinum toxin should not undergo prophylactic antitoxin; instead they require close medical observation in nonsolitary settings for evolving signs. This is active surveillance of a defined exposed cohort, distinct from population screening.^[11][12]

Because there is no screening, risk reduction depends on primary prevention (no honey before 12 months; safe home-canning/pressure processing; adequate refrigeration of processed foods; harm reduction for injection drug use), which is addressed in the Primary Prevention microchapter and only cross-referenced here.^[13][14]

• Do not order botulism toxin testing to screen asymptomatic people; test only symptomatic patients, and treat on clinical suspicion without awaiting results.^[15]
• Report any suspected case immediately to the state health department (or CDC after hours); reporting substitutes for screening as the population-level safeguard.^[16]
• Observe, do not prophylactically treat, asymptomatic exposed persons in a monitored, nonsolitary setting.^[17]

Botulism is characterized by an acute, afebrile, symmetric, descending flaccid paralysis that begins with cranial-nerve dysfunction and may progress to respiratory failure and death. The tempo of onset and progression depends on the neurotoxin dose, ranging from hours to several days. Death results chiefly from airway obstruction (pharyngeal paralysis) and respiratory-muscle/diaphragmatic failure. With modern intensive care and timely antitoxin, most patients survive, but recovery requires new motor nerve-terminal regeneration and therefore takes weeks to months; a substantial minority have persistent fatigue, dyspnea, weakness, and autonomic symptoms for a year or longer.^[1][2][3]

• Foodborne: usually 12–48 hours (range, 6 hours–10 days) after ingestion of preformed toxin.
• Infant: estimated 3–30 days from spore ingestion.
• Wound: 4–14 days from injury to symptom onset.

Immunity does not develop after infection, and botulism is not transmitted person to person.^[4]

After cranial-nerve involvement (diplopia, ptosis, dysarthria, dysphagia, dysphonia), weakness descends symmetrically to the trunk, limbs, and respiratory muscles. Because botulinum toxin irreversibly binds the presynaptic terminal and the cleaved exocytosis complex requires up to ~4 weeks to regenerate, paralysis is prolonged; antitoxin halts progression but does not reverse established paralysis. In a large foodborne outbreak (home-canned bamboo shoots, Thailand), ~30% of hospitalized patients required mechanical ventilation. Untreated or unsupported severe disease progresses to fatal respiratory failure.^[5][6]

• Respiratory failure — the principal life-threatening complication, from diaphragmatic/intercostal weakness and pharyngeal collapse; may develop early and abruptly.^[7]
• Aspiration from bulbar dysfunction (dysphagia, pooled secretions, depressed gag).^[8]
• Autonomic dysfunction — dilated/fixed pupils, xerostomia, ileus, urinary retention, orthostatic hypotension, and labile heart rate/blood pressure.^[9]
• Nosocomial complications of prolonged critical illness — ventilator-associated pneumonia and other hospital-acquired infections are a major cause of death; fever is otherwise absent in botulism and suggests secondary infection.^[10]

Recovery depends on regeneration of functional nerve terminals and is slow. Severe cases may require weeks to months of mechanical ventilation. Most survivors regain normal ventilatory muscle strength within about one year, but persistent symptoms are common and often underappreciated.^[11]

In the first systematic review of botulism sequelae (2026), the most frequently reported long-term symptoms among survivors were fatigue (~66%), general weakness (~57%), limitation in vigorous activity (~56%), and dyspnea (~43%). Ocular and bulbar symptoms tend to resolve faster than autonomic (dry mouth, constipation) and muscular symptoms; psychosocial dysfunction (anxiety, depression) may persist for years and can outlast physical impairment. Mechanical ventilation and older age predict worse long-term health.^[12][13] Treated infants generally recover fully, with normal strength and neurodevelopment on follow-up.^[14]

• Overall / foodborne: contemporary mortality is approximately 5%, but may be as high as ~10% even among antitoxin-treated patients, usually from respiratory failure or sequelae of paralysis. Global figures vary widely by era and access to critical care (historically reported range ~2.5%–44%).^[15][16][17]
• Infant: case-fatality is very low (<1%) among hospitalized infants receiving modern care.^[18]

• Antitoxin timing is the key modifiable determinant: any antitoxin reduces mortality (OR ~0.16), and administration within 48 hours confers greater benefit (OR ~0.12); no interval was identified beyond which antitoxin lacked benefit. Administration >48 hours after onset is associated with longer ICU/hospital stays and decreased survival. Earlier antitoxin also shortens duration of mechanical ventilation and hospitalization. Earlier antitoxin administration also correlates with shorter ventilator dependence; in one outbreak, median ventilator duration was progressively longer when antitoxin was given on day 2 versus day 4 versus day 6 after exposure.^[19][20][21]
• Age >60 years carries higher mortality.^[22]